Obesity commonly accompanies hypertriglyceridemia, and weight reduction is widely recommended for treatment of elevated triglyceride levels. To determine whether weight reduction will normalize lipoprotein metabolism in overweight, hypertriglyceridemic patients, 10 such male patients underwent weight loss until their body weights were within the desirable range. After reestablishment of a steady state in body weight at the lower level, measurements were made of plasma lipid, lipoprotein, and apolipoprotein levels and the kinetics of low density lipoprotein (LDL) apolipoprotein B-100 (apo B) and apolipoprotein A-I (apo A-I). The patients lost an average of 10.6±2.1 kg (mean±SEM). Plasma triglyceride concentrations fell from 431 ±42 mg/dl to 248±27 mg/dl (p<0.001), whereas concentrations of total cholesterol, LDL cholesterol, total apo B, and high density lipoprotein (HDL) cholesterol were unchanged after weight loss. On average, the fractional catabolic rates (FCRs) for LDL were much higher in the patients after weight loss than in 16 normal control subjects (0.55 ±0.06 versus 0.31±0.06 pool/day), and input rates for LDL also were higher for hypertriglyceridemic patients after weight loss (22.2±2.4 versus 12.8±2.3 mg/ kg • day). Compared with 20 normal control subjects, hypertriglyceridemic patients after weight reduction had persistent low HDL cholesterol levels (32±2 versus 54±3 mg/dl) as well as low apo A-I levels (99±5 versus 122 ±4 mg/dl). In addition, the patients had higher FCRs for apo A-I than did control subjects (0.271 ±0.016 versus 0.198±0.012 pool/day), but input rates were not significantly different (11.24±0.64 versus 10.50±0.50 ing/kg • day). Thus, despite weight reduction, several abnormalities in lipoprotein levels and apolipoprotein kinetics persisted. ( 
M
any patients with hypertriglyceridemia are overweight, and obesity commonly is accompanied by high plasma triglyceride levels. 1 " 5 Consequently, weight reduction is generally recommended as the primary therapy for patients with hypertriglyceridemia. 6 ' 7 When weight loss lowers triglyceride levels to the normal range, the hypertriglyceridemia generally is considered to be "cured." Growing evidence, however, indicates that many individuals possess latent defects in metabolism of trigrycerides that render such individuals susceptible to developing hypertriglyceridemia. These defects probably consist largely of abnormalities in the capacity for catabolism of trigh/ceride-rich lipoproteins. 8 -11 In patients who have these defects, hypertriglyceridemia may be elicited by provocative factors such as obesity or excess alcohol intake. Evidence for the occurrence of latent defects in triglyceride catabolism come mainly from studies of the kinetics of very low density lipoprotein (VLDL) triglycerides. 8 - 10 The results of these studies suggest that some people sluggishly clear plasma triglycerides even without hypertriglyceridemia. Sane and Nikkila 10 recently reported a genetic basis for this phenomenon. If subtle defects of this type actually occur, lipoprotein metabolism might be defective even when affected patients are not subject to provocative factors and thus are not hypertriglyceridemic.
Previous investigations 12 -14 have shown that obese, hypertriglyceridemic patients manifest abnormalities in the kinetics of both low density lipoproteins (LDLs) and high density lipoproteins (HDLs). The present study therefore was performed to determine whether such abnormalities persist after near normalization of triglyceride levels by weight reduction in hypertriglyceridemic patients who are mildly to moderately overweight. This question was addressed by determining the kinetic parameters of LDL-apolipoprotein B-100 (apo B) and apolipoprotein A-I (apo A-I) in patients with primary hypertriglyceridemia in whom triglyceride levels were lowered by weight loss. 
Methods

Patients
Ten patients who were mildly to moderately overweight participated in this investigation. All patients' weights exceeded desirable body weight by more than 10%; the desirable weight was taken as the mean desirable weight for a given height in the Metropolitan Life Insurance tables of 1983. 15 Participants in this study were originally outpatients of the Veterans Affairs Medical Centers, Dallas and Bonham, Tex. Patients who were noted to have elevated triglyceride levels as outpatients were admitted to the metabolic ward for 3 days of evaluation to determine eligibility for admission into the study. They were selected for the protocol if they were mildly to moderately overweight and had plasma triglyceride levels that exceeded 300 mg/dl on 3 consecutive days while on the metabolic ward for evaluation. Those with triglyceride levels exceeding 1,000 mg/dl were not included. Patients also were excluded from the study either if they had endocrine disorders, including diabetes mellitus, liver disease, or severe dysfunctional cardiopulmonary disease or if they were taking /J-adrenergic blocking agents. They were not excluded if they had a history of coronary heart disease (CHD), as manifested by a history of myocardial infarction or coronary artery bypass surgery, provided that neither had occurred within 6 months before entering the study. Characteristics of the subjects at entry are shown in Table 1 , and average values are given as mean±SEM. The men had an average age of 56±3 years. At entry, the patient's body mass indexes (BMIs) averaged 27.5±0.6 kg/m 2 , which corresponds to 121% of desirable body weight (see Table 2 ). Plasma total cholesterol and triglyceride levels at the time of entry averaged 238±11 and 427±27 mg/dl, respectively. Lipoprotein cholesterol concentrations during evaluation were determined by Lipid Research Clinics techniques 16 ; VLDL cholesterol concentrations consistently exceeded the 95th percentile for American men, whereas the average level of HDL cholesterol was below the 10th percentile. 17 
Experimental Design
On recruitment, all patients gave written informed consent to participate in a study that was approved by the Institutional Review Board. After selection, they were instructed to start a weight-maintenance, solidfood diet consisting of 40% of total calories as fat (18% saturates, 17% monounsaturates, and 5% polyunsaturates), 45% as carbohydrate, and 15% as protein. Daily cholesterol intake averaged 450 mg/day. The patients followed this diet for a period of 5 weeks, and during the last week, five samples of blood were drawn on consecutive days for measurements of plasma lipids, lipoprotein cholesterol, and apolipoproteins. This baseline period was followed by a period of caloric restriction; for the purpose of weight reduction, patients received a liquid diet consisting of 1,000 kcal/ day. The liquid-formula diet consisted of the commercial product Sustacal (Mead Johnson, Evansville, Ind.), which contained 21% of calories as fat (partially hydrogenated soy oil), 24% protein, and 55% carbohydrate. Vitamin and mineral supplements were given to meet requirements. The period of weight reduction ranged from 42 to 112 days depending on the degree of overweight and the time required to reach the target for weight reduction. The aim of weight reduction was to bring body weight to less than 10% above the desirable level. After completion of weight reduction, patients started the same 40%-fat diet used previously to establish baseline values. Energy intake on this diet was adjusted to maintain the new lower weight. At the end of the third week or beginning of the fourth week of weight maintenance, one unit of blood was removed; 200 ml plasma was taken, and formed elements were returned to the patient. The plasma was used to isolate autologous LDL and apo A-I, and these two entities were labeled with different isotopes of radioiodine. Patients were admitted to the metabolic ward the night before simultaneous injection of the two tracers. Injections of isotopically labeled lipoproteins were done 1 week after plasmapheresis, and at least 4 weeks elapsed between starting the weight maintenance diet and injection of tracers. A previous study from our laboratory 18 has shown that 4 weeks of weight maintenance allows a return to the steady state after completion of weight loss in overweight subjects. After injection of isotopes, the patients remained in the hospital for 14 days while completing their turnover studies. Potassium iodide was administered daily to suppress thyroidal uptake of radioiodine. During the 14-day study, five samples were taken at spaced intervals for measurements of plasma lipids, lipoprotein cholesterol, and apolipoproteins.
Analysis of Lipids and Lipoproteins
For each of the latter samples, 10 ml blood was collected into EDTA. Plasma was separated immediately after collection and transferred into tubes that contained a final concentration of 0.005% gentamicin sulfate, 0.005% chloramphenicol, 0.01% NaN 3 , and 100 IU/ml aprotinin. Plasma total cholesterol and triglycerides were determined by using enzymatic methods. 19 -20 Determinations of lipoprotein cholesterol levels were made according to the Lipid Research Clinics laboratory manual, 16 except that the cholesterol in HDL was measured enzymatically. On a separate aliquot of plasma, lipoproteins of density < 1.019 g/ml were isolated by preparative ultracentrifugation, 21 and cholesterol concentration was measured enzymatically in the supernatant and infranatant. Recoveries during isolation and measurement exceeded 96%, and corrections were made for recovery. The fraction of lipoproteins of density < 1.019 g/ml was designated VLDL plus intermediate density lipoprotein (VLDL+IDL). LDL cholesterol concentrations were estimated as the difference between plasma total cholesterol levels and the combined total of VLDL+IDL cholesterol and HDL cholesterol levels. In standard Lipid Research Clinics terminology, 16 the fraction called LDL actually consists of LDL+IDL, whereas in this study, LDL corresponded to lipoproteins of density 1.019-1.063 g/ml.
Kinetics of LDL-Apo B and Apo A-I
The kinetics of LDL-apo B and apo A-I were determined simultaneously, as indicated above. Both LDL and apo A-I were isolated from 200 ml plasma. LDLapo B was labeled with 125 I and apo A-I with 131 I. Procedures for preparation of these two tracers and measurement of kinetic parameters are described below. After preparation, both tracers were injected into the patients simultaneously.
LDL-apo B kinetics. For determination of parameters of LDL-apo B kinetics, lipoproteins of density 1.019-1.063 g/dl, called "true LDL," were isolated according Lindgren et al. 21 LDL was resuspended in a salt solution of 1.065 g/ml density and recentrifuged to concentrate and remove any contaminating albumin. The lipoprotein was radiolabeled with & l by the method of McFarlane, 22 as modified for lipoproteins.
12^3 Excess iodine was removed by complete dialysis against 150 mM NaCl and 0.27 mM Na 2 EDTA (pH 7.4). A mixture of 5% human serum albumin, unlabeled autologous LDL, and 20-45 jtCi 125 I-LDL was prepared for intravenous injection. Blood samples were collected into vacuum tubes containing Na 2 EDTA, and plasma was isolated for counting. Twenty-three blood samples were collected during the 14-day period of the turnover study, and radioactivity was measured in each sample of plasma. Lipoprotein analyses, detailed above, were carried out on samples obtained on days 1, 4, 8, 12 , and 14 of the study. These analyses included determination of LDL apo B levels. The latter were determined on the true LDL fraction (d= 1.019-1.063 g/ml) isolated by preparative ultracentrifugation. The cholesterol content of LDL was determined enzymatically, and protein (apo B) was measured according to Lowry et al, 24 as modified by Markwell et al 25 and described previously. 26 The absolute plasma level of LDL apo B was estimated by multiplying the absolute concentration of LDL cholesterol (as determined above) by the LDL apo B -t ocholesterol ratio (determined on the isolated LDL fraction). The LDL apo B concentration for each patient was taken as the mean of the five measurements. VLDL+IDL-apo B levels were estimated simultaneously by a similar procedure on the VLDL+IDL fraction.
The fraction of 125 I radioactivity remaining in plasma was plotted as a function of time, and the resulting disappearance curve was used to calculate fractional catabolic rates (FCRs) for LDL. The curves were consistently biexponential and were assumed to conform to a two-pool model 27 ; according to this model, input and exit of LDL occurred from an intravascular pool that was in equilibrium with an extravascular pool. The FCR was estimated by simulation analysis. The size of the intravascular pool of LDL apo B was determined by multiplying the concentration of LDL apo B by the plasma volume. The plasma pool size for LDL apo B was estimated by isotope dilution from the sample taken at 10 minutes. The input rate (transport rate) for LDL apo B was estimated as the product of pool size and FCR for LDL apo B.
For purposes of comparison, the current results for LDL turnover are compared with those of 16 normal subjects reported previously. 28 These subjects were men whose average age was 55 ±12 years (mean±SD) and whose LDL cholesterol concentrations ranged from the 25th to 75th percentile for age and sex in the Lipid Research Clinics Prevalence study. 17 LDL-apo B kinetics were performed in these subjects by identical techniques to those used in the current study. These subjects had the following characteristics expressed as mean±SEM: BMI, 24.6±1.1 kg/m 2 ; total cholesterol, 202±5 mg/dl; total triglyceride, 138±13 mg/dl; and LDL cholesterol, 137±4 mg/dl.
Kinetics of Apo A-I
The procedure for estimating turnover rates of apo A-I has been described recently. 29 Briefly, HDL (d= 1.090-1.21 g/ml) was obtained from plasma by sequential preparative ultracentrifugation by the method of Lindgren et al. 21 The isolated HDL was resuspended at its native density and recentrifuged in a TV-865B vertical rotor (DuPont Sorvall, Wilmington, Del.) for 2.5 hours at 65,000 rpm to remove any contaminating proteins. An aliquot of purified HDL was used to isolate autologous A-I according to the following procedure. HDL containing approximately 9 mg protein was dialyzed against 150 mM NaCl, 10 mM tris(hydroxymethyl)aminomethane (Tris) chloride, and 0.01% Na 2 EDTA, pH 8.0. The dialyzed solution containing HDL was transferred to a sterile, pyrogen-free vial, and 1.146 mg guanidine hydrochloride was added to bring the solution to 4 M. This solution was incubated for 3 hours at 37°C and then dialyzed against 150 mM NaCl, 10 mM Tris chloride, and 0.01% EDTA, pH 8.0. After dialysis, the solution was transferred to a sterile 6-ml ultraclear centrifuge tube, and the density was adjusted to 1.21 g/ml with solid sodium bromide. The solution was overlayered with an equal volume of sodium bromide solution of similar density, and the mixture was subjected to ultracentrifugation at 50,000 rpm for 24 hours in a 50.3 fixed-angle rotor (Beckman Instruments, Palo Alto, Calif.) at 10°C. The bottom 1.5 ml was collected and dialyzed extensively against 150 mM NaCl, 0.01% EDTA, pH 7.4. The concentration of protein was determined by the procedure of Lowry et al, 24 as modified by Markwell et al 25 and described previously. 26 The purity of apo A-I was verified immunochemicalry 30 and electrophoretically. 31 Approximately 1 mg autologous apo A-I was radiolabeled with 131 I by the method of McFarlane, 22 as modified in our laboratory. 12 Free iodine was removed from the preparation by dialysis against 150 mM NaG, 10 mM Tris chloride, and 0.01% EDTA, pH 8.0. In the labeled apo A-I preparation, 99% of the radioactivity was precipitable by 15% trichloroacetic acid. When the preparation was subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis, all of the radioactivity was associated with a single band that corresponded to apo A-I.
An injection mixture containing 4% human serum albumin and 25-30 ^.Ci of the tracer was injected intravenously. Twenty-three blood samples were collected over a period of 14 days, as described above. Four milliliters of plasma was counted for each time point, and the fraction of injected dose was calculated for each sample. The residence time was calculated by using a two-pool model. 27 The transport rate was calculated by dividing the pool size of plasma apo A-I by the residence time. The former was estimated as the product of plasma apo A-I concentration and plasma volume (i.e., volume of distribution of apo A-I as determined by the 10-minute sample). Concentrations of plasma apo A-I were determined by a modification of the electroimmunoassay of Laurell.
32 Polyclonal anti-human apo A-I antisera were obtained from Boehringer-Mannheim Corp. (Biochemical Products, Indianapolis, Ind.). The electrophoresis gel consisted of 1.25% antisera, 2% (wt/vol) agarose (Seakem agarose, 0.16-0.19 relative mobility electroendosmosis; Marine Colloids Division, FM Corp., Rockland, Me.), 2% (wt/vol) dextran (molecular weight =70,000; Sigma Chemical Co., St. Louis, Mo.), and a Monotony buffer. 33 The standard used was a serum calibrator for apo A-I obtained from Boehringer-Mannheim Diagnostics. This standard was recalibrated in our laboratory by electroimmunoassay with pure apo A-I as the primary standard. Concentrations were calculated from peak heights. The coefficient of variation for each assay was determined; each assay had 5% or less variation within and between assays. For comparison, apo A-I turnover measurements were carried out in 20 normal subjects of average age 56 ±2 years (mean±SEM) and average BMI 23.6±0.7 kg/m 2 (mean±SEM). These subjects had normolipidemia (total cholesterol <250 mg/dl [mean±SEM, 213±6 mg/dl] and trigrycerides <250 mg/dl [mean±SEM, 99±8 mg/dl] and normal HDL cholesterol levels (s40 mg/Jl [mean±SEM, 54±3 mg/dl]). They did not have a history of CHD, nor did they smoke or take /3-adrenergic blocking agents. They underwent the same apo A-I turnover study as the current patients.
Results
Weight Changes
The changes in weight reduction for the 10 patients are presented in Table 2 . Weight losses ranged from 4.6 to 24.5 kg, averaging 10.6±2.1 kg (mean±SEM). All patients except one (No. 6) reduced their body weight to <10% above estimated desirable body weight. Patient No. 6 lost 10.2 kg and went from 131% to 116% of desirable body weight. The mean (±SEM) BMI after weight loss was 24.2±0.3 mg/kg 2 ; this value approximated the mean BMI of both control groups.
Triglycerides and VLDL+IDL Cholesterol
Weight reduction produced an average decrease in total triglycerides of 42%, whereas VLDL+IDL cholesterol levels declined by 34% (Table 3) . In three patients, triglyceride levels fell to <200 mg/dl; in five others, levels declined to <300 mg/dl; and in only two patients were levels in the range of 300-400 mg/dl after weight loss. For each patient, the average triglyceride levels after weight loss were compared with the value for the 95th percentile for American men of the same age in Table 3 . 17 In many cases, triglyceride levels after weight loss were near the 95th percentile for men of the same age. Table 4 gives values for concentrations of total cholesterol and total apo B before and after weight loss. Although several patients had a decrease in levels of both total cholesterol and total apo B with weight loss, others had increases in these parameters. On average, weight reduction failed to produce significant changes in either total cholesterol or total apo B.
Total Cholesterol and Total Apo B
LDL Metabolism
Weight reduction, on average, did not cause a decrease in LDL cholesterol levels (Table 5 ). In fact, the average LDL cholesterol concentration increased numerically after weight loss, although the increase was not statistically significant. Concentrations of LDL-apo B after weight reduction were similar to those of normal control subjects. Nonetheless, FCRs for LDL, on average, were much higher than those of control subjects, as were input rates for LDL. In only three patients (Nos. 4, 6, and 7) were FCRs and input rates for LDL-apo B in the control range after weight reduction. Thus, only these three patients appeared to have a "normal" metabolism of LDL after weight loss; the majority had persistent high flux rates for LDL-apo B after weight reduction.
HDL and Apo A-I Metabolism
As shown in Table 6 , a few patients had rises in HDL cholesterol levels after weight loss, whereas others had decreases; for the group as a whole, however, HDL cholesterol levels were not significantly different before and after weight loss. Clearly, HDL cholesterol concentrations in these patients were still markedly reduced even after weight reduction. Likewise, after weight loss, concentrations of apo A-I remained low. For individual patients as well as for the whole group, FCRs for apo A-I remained abnormally high after weight loss. Input rates for apo A-I, in contrast, were not significantly different from those in the control group. Consequently, the low apo A-I levels that persisted after weight loss were due primarily to increased FCRs for apo A-I. Discussion Plasma triglyceride concentrations of 150-300 mg/dl that occur in the presence of relatively normal levels of LDL cholesterol are considered by some investigators to be innocuous. 34 - 35 Moreover, when moderate hypertriglyceridemia occurs in overweight people, weight reduction generally is believed to correct the condition. Thus, obesity is commonly thought to be the major cause of hypertriglyceridemia, and if so, weight reduction logically would be a relatively simple remedy. This belief is consistent with the view that most cases of mild-tomoderate hypertriglyceridemia are secondary to lifestyle characteristics -obesity, excess alcohol intake, and lack of exercise -and consequently, elevated triglyceride levels in this range should yield to changes in these life habits. This position was taken by the Institutes of Health Consensus Conference on Triglycerides in 1983, 6 as well as the American Heart Association in its recommendations for treatment of hyperlipidemia 36 and the National Cholesterol Education Program's guidelines for treatment of high blood cholesterol in adults. 7 On the other hand, several lines of evidence call this simplistic concept into question. First, most overweight people do not have elevated triglyceride levels, a finding that suggests that those who do possess a separate abnormality in tnglyceride metabolism. A previous report 37 from our laboratory indicated that obese patients with normotriglyceridemia as well as with hypertriglyceridemia have overproduction of VLDL triglycerides. Obese subjects having normal triglyceride levels were able to cope with an increased input of VLDL triglyceride by enhanced catabolism, whereas those with elevated triglyceride levels exhibited a sluggish clearance. 38 We therefore speculated that some normal-weight people have a "latent" defect in triglyceride catabolism 9 ; however, these people are protected from hypertriglyceridemia because of relatively low production rates for VLDL triglycerides. Should these people become obese, they would develop hypertriglyceridemia. This same line of reasoning has been forwarded by Nikkila and coworkers 8 -10 ; they postulated a genetic variability in the capacity to hydrolyze triglyceride-rich lipoproteins, and according to their view, hypertrigryceridemia occurs only in individuals having the combination of a genetic "defect" in VLDL triglyceride metabolism and obesity.
Patients with definite hypertrigryceridemia typically have low levels of HDL cholesterol, and these low levels usually are accompanied by enhanced rates of catabolism of apo A-I.
14 Furthermore, hypertriglyceridemic patients almost always have striking increases in both FCRs and flux rates for LDL apo B.
-
13 Various reports 11 -39 -41 also indicate that low HDL cholesterol levels, a strong predictor of CHD risk, frequently are present in people who have high-normal or only mildly elevated triglyceride concentrations. The combination of mildly high triglyceride and low HDL cholesterol levels has been recognized increasingly as a common lipoprotein profile in patients with CHD. 42 -43 In addition, slightly elevated triglyceride concentrations have been linked to an abnormality in LDL composition, notably, small, dense LDL particles 44 ; these particles likewise are implicated in the causation of coronary atherosclerosis. 45 Thus, there is increasing evidence that the syndrome of mild hypertrigryceridemia; low HDL cholesterol levels; and small, dense LDL particles constitutes an "atherogenic" lipoprotein profile. Patients with this profile might be said to have a dyslipidemia syndrome, i.e., a syndrome consisting of abnormalities in all lipoprotein fractions without hyperlipidemia (i.e., without elevated total cholesterol and/or definitely high triglyceride values).
An important question is whether weight reduction will correct concomitant abnormalities in lipoprotein metabolism that occur in patients with mild-to-moderate hypertrigryceridemia, as implied in previous recommendations for the management of hypertriglyceridemia. ) correspond to the 25th percentile for American men of the same age. 17 Thus, it is doubtful that any persistence of elevated triglyceride levels in this group could be attributed to residual obesity. Plasma triglyceride levels fell significantly, although most patients maintained high-normal to mildly elevated triglyceride concentrations (150-300 mg/dl) after weight loss; these very borderline elevated concentrations, despite elimination of almost all "excess" body fat, suggest that the patients had a mild defect in triglyceride metabolism. Most of these patients, however, would not be considered to have clinically significant hypertriglyceridemia by many investigators. 6 -7 In a few patients, weight reduction lowered plasma total cholesterol levels, but this response was not typical, and on average, the decrease was not statistically significant. Plasma total apo B levels likewise did not fall with weight loss in most patients. Moreover, LDL cholesterol levels often rose when triglyceride levels fell, as noted previously for hypertriglyceridemic patients. 46 -47 A striking abnormality in LDL metabolism was the persistence of a high flux rate for LDL-apo B despite a lowering of triglyceride level by weight reduction. These high flux rates, characterized by a marked increase in both input rates and FCRs for LDL apo B, were observed in seven of 10 patients. Whether this LDL abnormality increases risk for CHD independent of LDL cholesterol levels is unclear; nonetheless, Kesaniemi and Grundy 48 previously reported that a high flux of LDL commonly occurs in normolipidemic patients with premature CHD. Patients of the current study generally did not have elevated concentrations of LDL apo B, and hence the high-flux pattern for LDL occurred independent of hyperapobetalipoproteinemia and thus appears to be another high-risk abnormality.
Why a high flux of LDL accompanies mild hypertriglyceridemia is not entirely clear. Two possibilities, however, can be considered. First, there could be increased secretion of apo B-containing lipoproteins by the liver, resulting in increased conversion of VLDL to LDL; alternatively, hepatic uptake of VLDL remnants could be decreased, favoring the conversion of VLDL to LDL. We favor the latter mechanism on theoretical grounds because if VLDL particles are poor ligands for LDL receptors, more VLDL particles should be converted to LDL and more receptors would be available for removal of LDL. Indeed, the delivery of fewer cholesterol-rich VLDL might lead to an "upregulation" of LDL receptor synthesis. This mechanism thus could explain both the high input rate and high FCRs for LDL. An increased secretion of apo B-containing lipoproteins, on the other hand, should not lead to increased FCRs for LDL. Still, this possibility cannot be ruled out with certainty. The reason why a high flux of LDL per se should promote atherogenesis is not apparent, although it seems to be a common pattern in CHD patients 48 and might be accompanied by either an atherogenic change in LDL composition 44 - 45 or delivery of more LDL particles into the arterial wall.
A second abnormality that persisted after weight loss was a low HDL cholesterol concentration. Although weight reduction will raise HDL cholesterol levels in obese patients who are not hypertriglyceridemic, 18 this may not occur in patients who manifest elevated triglyceride values. The persistently low HDL cholesterol levels in current patients were accompanied by low levels of total apo A-I, which were due to high FCRs for apo A-I, not decreased input rates. A similar kinetic parameter commonly occurs in patients with more marked hypertriglyceridemia.
The low levels of HDL cholesterol and apo A-I in current patients almost certainly were secondary to hypertriglyceridemia, and their presence after weight loss undoubtedly can be explained by persistence of an underlying defect in triglyceride metabolism. How this abnormality leads to low HDL concentrations is not entirely clear, but there is no reason to question its atherogenic potential because a low HDL and mildly high triglyceride values are noted so commonly in patients with premature CHD. 42 -43 Several previous investigators have examined the effects of triglyceride lowering on the levels or metabolism of lipoproteins in patients with primary endogenous hypertriglyceridemia (type 4 hyperlipoproteinemia). For example, Witztum et al 49 reported that reduction of plasma trigh/ceride values by weight reduction or drug therapy failed to raise HDL cholesterol levels in a group of patients with type 4 hyperlipoproteinemia. Likewise, Vega and Grundy 47 noted that reduction of triglyceride levels by gemfibrozil therapy in patients with primary hypertriglyceridemia generally did not restore HDL cholesterol levels to normal; in addition, FCRs for LDL apo B, which were initially high, were lowered in several patients with drug therapy, but they remained elevated in most patients. Furthermore, Kissebah et al 50 normalized triglyceride levels in six patients with type 4 hyperlipoproteinemia by using a combination of clofibrate and carbohydrate restriction (not weight reduction), and in none of these patients did elevated FCRs for LDL apo B return to normal despite a triglyceride lowering. Finally, Ginsberg et al 51 examined the effects of weight reduction on LDL metabolism in six hypertrigryceridemic patients. In their study, percent desirable body weight fell from 132±7% (mean±SEM) to 119±6%, and VLDL triglyceride levels declined from an average of 486 mg/dl to 191 mg/dl. FCRs for LDL apo B initially were markedly elevated (0.68±0.12 pool/day), and with weight reduction they fell but remained elevated (0.48±0.04 pool/ day). Effects of weight loss on HDL levels in these patients were not reported. Whether further weight reduction to nearer the desirable range would have further normalized LDL metabolism in these patients cannot be predicted, but when the data from all these studies 4749 - 51 are considered together, they seemingly support the present findings, namely that reduction in triglyceride levels fails to eliminate abnormalities in LDL and HDL metabolism that accompany the hypertriglyceridemic state.
In conclusion, as shown in the current study, weight reduction in patients with primary hypertriglyceridemia definitely lowers plasma triglyceride levels, but a mild elevation of triglyceride values, indicative of a persistent abnormality in triglyceride metabolism, usually remains after weight loss. In this sense, obesity provides a "provocative test" for a primary defect in triglyceride metabolism, the latter being responsible for the dyslipidemia syndrome noted here. However, weight loss failed to correct the accompanying abnormalities in Iipoprotein metabolism in most patients, and just how much of a benefit for CHD risk reduction has been obtained by weight loss in these patients can be questioned. In general, after weight loss, total apo B levels were not reduced, and if anything, LDL cholesterol concentrations were increased; moreover, HDL cholesterol (and apo A-I) concentrations were not raised significantly, and certainly not to the normal range. In addition, our patients retained abnormalities in the kinetic behavior of both LDL apo B and apo A-I. Thus, we suggest that finding simultaneous increases in FCRs for both LDL-apo B and apo A-I in nonobese patients with high-normal triglyceride levels suggests the presence of a latent defect in triglyceride metabolism. It is interesting to speculate whether a defect in trigh/ceride metabolism as seen in our patients is responsible for the "atherogenic Iipoprotein phenotype" reported by Austin, Krauss, and their associates 44 -45 -52 ; they indicate that this phenotype is characterized by slightly high trigh/ceride values; small, dense LDL particles; and reduced levels of HDL.
The current study does not rule out a potential benefit of weight reduction in hypertriglyceridemic patients who are mildly to moderately overweight; on the other hand, weight loss cannot be considered the definitive therapy for dyslipidemia in patients of this type because abnormalities persist after weight reduction. Several lines of evidence indicate that these persistent abnormalities are risk factors for CHD. Another form of treatment aimed more specifically at the underlying defect in triglyceride metabolism is needed. This need presents a challenge to better define the nature of the defects in triglyceride metabolism that are responsible for the persistence of the dyslipidemia syndrome after restoration of normal body weight.
